TOKYO -- SoftBank Group-backed U.S. biotech startup Relay Therapeutics gained 75% on its trading debut on Nasdaq, raising hopes for a recovery in the performance of Softbank's $100 billion Vision Fund.
SoftBank
Biotech IPO raises hopes for SoftBank Vision Fund rebound
Relay Therapeutics jumps 75% in Nasdaq debut
SoftBank Group CEO Masayoshi Son, pictured last year, with the Relay Therapeutics logo. The Softbank-backed biotech startup has gone public on Nasdaq. (Source photos by Ken Kobayashi)
Read Next
%2520%E3%82%BD%E3%83%95%E3%83%88%E3%83%90%E3%83%B3%E3%82%AF%E3%82%B0%E3%83%AB%E3%83%BC%E3%83%97%E3%80%80%E6%B1%BA%E7%AE%97%E7%99%BA%E8%A1%A820200629174437908_Data.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on SoftBank
